Aura Biosciences, Inc.

For the period ended Dec 31, 2025. Filed Mar 30, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 30, 2026

AURA$7.66+16.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Aura Biosciences, Inc.
Date: March 30, 2026	By:	/s/ Elisabet de los Pinos
		Elisabet de los Pinos
		President and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

Elisabet de los Pinos
Name	Title	Date
/s/ Elisabet de los Pinos	President and Chief Executive Officer (Principal Executive Officer)	March 30, 2026
/s/ Anthony Gibney	Chief Financial and Business Officer (Principal Financial Officer)	March 30, 2026
Anthony Gibney
/s/ Amy Elazzouzi	Senior Vice President, Finance (Principal Accounting Officer)	March 30, 2026
Amy Elazzouzi
/s/ David Johnson	Chairman of the Board of Directors	March 30, 2026
David Johnson
/s/ Teresa Bitetti	Director	March 30, 2026
Teresa Bitetti
/s/ Giovanni Mariggi	Director	March 30, 2026
Giovanni Mariggi
/s/ Antony Mattessich	Director	March 30, 2026
Antony Mattessich
/s/ Sapna Srivastava	Director	March 30, 2026
Sapna Srivastava
/s/ Karan Takhar	Director	March 30, 2026
Karan Takhar

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.